Development of Adenosine Deaminase-Specific IgY Antibodies: Diagnostic and Inhibitory Application
Adenosine deaminase (ADA) is currently used as a diagnostic marker for tuberculous pleuritis. Although ADA has been suggested as a potential marker for several types of cancer, the importance of each of ADA isoforms as well as their levels and enzymatic activities in tumors need to be further investigated. Herein we developed avian immunoglobulin Y highly specific to human ADA via hens immunization with calf adenosine deaminase. The obtained antibodies were used for the development of a sensitive double-egg yolk immunoglobulin (IgY) sandwich ELISA assay with an ADA detection limit of 0.5 ng/ml and a linearity range of up to 10 ng/ml. Specific, affinity-purified IgYs were able to recognize human recombinant ADA and ADA present in human cancer cell lines. In addition, antigen-specific IgY antibodies were able to inhibit catalytic activity of calf ADA with an IC50 value of 47.48 nM. We showed that generated IgY antibodies may be useful for ADA detection, thus acting as a diagnostic agent in immunoenzymatic assays.
KeywordsEgg yolk immunoglobulin (IgY) Adenosine deaminase (ADA) Anti-adenosine deaminase antibody Affinity purification Enzyme inhibition ELISA
Adenosine deaminase small form
Adenosine deaminase large form
Calf adenosine deaminase
Human adenosine deaminase
Basic Local Alignment Search Tool
- CA 15-3
Cancer antigen 15-3
Enzyme-linked immunosorbent assay
Human anti-mouse antibody
Human epidermal growth factor family receptor-2/Neu
Phosphate-buffered saline with Tween
Polyacrylamide gel electrophoresis with sodium dodecyl sulfate
In human body fluids and tissues, adenosine deaminase (adenosine aminohydrolase, EC 126.96.36.199) is present as two isozymes: ADA1 and ADA2. Both isozymes play an essential role in purine nucleoside metabolism catalyzing the irreversible deamination reaction of adenosine or 2′deoxyadenosine to inosine or 2′deoxyinosine. These two isozymes are kinetically distinguishable by their reaction with EHNA ((+)-erythro-9-(2-hydroxy-3-nonyl)adenine), a specific inhibitor of ADA1 .
The ADA1 isozyme is ubiquitous in all human tissues and erythrocytes with a small amount circulating in plasma . ADA1 exists in two molecular forms: the small monomeric adenosine deaminase (ADA1-S, 41 kDa) and the large adenosine deaminase (ADA1-L, 298 kDa), which is composed of ADA1-S and adenosine-binding protein (dipeptidyl-dipeptidase IV (DPPIV) or CD26) [3, 4, 5, 6]. The small globular ADA1-S molecule is formed by a characteristic parallel α/β-barrel motif (TIM barrel fold) with a zinc cofactor located in the catalytic pocket . Interacting with ADA, dipeptidyl peptidase mediates co-stimulatory signals in T-lymphocytes. The protein-protein contact between these two molecules occurs through two hydrophobic loops in the β-propeller domain of DPPIV and two hydrophilic α-helices within ADA, which is why even after the formation of the complex both enzymes remain catalytically active .
The second isozyme [ADA2] belongs to the adenosine deaminase growth factor family. It is found in monocytes and represents the main ADA isozyme present in human plasma and serum (originating from monocytes-macrophages) . ADA2 exists as an extensively glycosylated functional homodimer (110 kDa) with a signal peptide and a conserved disulfide bond [4, 10, 11]. According to Zavialov et al., the ADA1-like domain of the ADA2 isozyme shares approximately 70% of its total amino acid sequence similarity with the ADA1 protein, but with only 20% of amino acid identity .
According to experimental data presented by Kelly et al., there is 93% sequence identity between bovine and human ADA . Simple sequence alignment using the protein Basic Local Alignment Search Tool (BLAST) algorithm indicates no gaps between the two sequences, and 91% of amino acid residues are identical (94% represent positives: 1VFL.pdb and 3IAR.pdb). The high homology of these proteins was the reason we selected calf ADA as a target protein for the development of egg yolk immunoglobulin (IgY) antibodies described in this manuscript.
In a healthy organism, the tissue and blood concentration of adenosine, an important signaling metabolite, is low and its extracellular physiological level does not exceed 1 μM [13, 14]. Local adenosine concentration increases significantly during inflammation, ischemia, or hypoxia and can reach 100 μM [14, 15, 16]. Adenosine’s effect is contingent on the cell type: it may serve as a cytoprotective agent, stimulate angiogenesis, and decrease inflammation. On the other hand, the necrosis- and hypoxia-induced release of adenosine may result in the enhancement of angiogenesis and promotion of tumor growth . An increased activity of ADA in malignant tissues is associated with their compensatory mechanism against toxic levels of adenosine, deoxyadenosine, and its derivatives which are potent inhibitors of ribonucleotide reductase (RNR), a rate-limiting step of nucleotide biosynthesis . The activity of RNR is particularly important for cells that undergo division . ADA-catalyzed deamination of adenosine and 2′deoxyadenosine leads decreased levels of intermediates acting as RNR inhibitors. Therefore, some ADA inhibitors (such as erythro-9-(2-hydroxy-3-nonyl)adenine, EHNA) induce apoptosis of malignant tumor cell lines and suppress tumor growth by increasing intracellular adenosine/deoxyadenosine concentration . Furthermore, pentostatin (2′-deoxycoformycin), approved by the FDA for the treatment of chronic B-cell lymphoproliferative disorders, is a nucleoside analog which non-competitively inhibits ADA and leads to an accumulation of adenosine metabolites that inhibit RNR .
An increased serum level/activity of ADA is often observed during the development of breast, bladder, ovarian, head and neck, and laryngeal cancer [22, 23, 24, 25, 26, 27]. An increased activity of ADA was also observed in cancerous colorectal tissues as well as in saliva from patients suffering tongue squamous cell carcinoma [28, 29]. ADA as a diagnostic marker is routinely used for the diagnosis of tuberculous pleuritis with a high degree of specificity and sensitivity [30, 31]. It is important to highlight that different isozymes/molecular forms of ADA have been found in tumor cells, which may indicate that the composition of isoforms during cancer progression may change [32, 33].
Considering the advantages of IgY antibodies as diagnostic tools, we decided to generate ADA1-specific avian IgYs. After immunization, the IgY class of immunoglobulins is isolated from chicken egg yolks, so in contrast to the production of mammalian antibodies, no animal bleeding is necessary. Additionally, the cost of IgY antibodies is significantly lower than that of their mammalian equivalents without deteriorating their quality [34, 35]. The IgY technology makes it possible to obtain more than 1000 mg of antibodies (of which 2–10% are antigen-specific) from one hen within 2 weeks while a parallel isolation of rabbit IgG yields approximately 200 mg with 5% antigen-specific immunoglobulins . The use of IgY antibodies in serological diagnostics reduces the risk of false-positive results, since IgYs do not interact with the rheumatoid factor, components of the complement system, or human anti-mouse IgG . Indeed, the incidence of false results may be as high as 12%, thus the reduction of false positives is crucial for improved serum diagnostics . A considerable advantage of antibodies generated in the hen as a host organism is the evolutionary distance between mammals and birds. It is rather challenging to obtain antibodies specific towards conserved mammalian antigens in mammalian systems whereas the same antigens are highly immunogenic for hens .
Until now, hen immunoglobulins have been developed as diagnostic tools for infectious agents including Listeria monocytogenes, Escherichia coli, and Mycobacterium avium subsp. paratuberculosis as well as tumor markers such as thymidine kinase 1, Human epidermal growth factor family receptor-2/Neu (HER2) and telomerase, kallikrein 6 (KLK6), cancer antigen 15-3 (CA 15-3), and KLK3 [40, 41, 42, 43, 44, 45, 46, 47]. IgY antibodies can also be used as neutralizing, anti-toxin agents and for passive immunization. Specific IgY antibodies obtained after immunization with the recombinant Shiga toxin-2 (Stx2) subunit are able to effectively block the biological activity of Stx2, one of the main virulence factors of E. coli . IgYs specific to Solobacterium moorei exhibit the potential to inhibit their growth and biofilm formation . At present, as an alternative to mammalian anti-sera, avian immunoglobulins are produced as an anti-venom agent neutralizing Naja, Bitis, coral snake, and Brazilian Bothrops toxins [49, 50, 51, 52].
Considering the importance of ADA as a disease marker, we have decided to generate avian antibodies and develop an IgY-based sandwich-type ELISA assay for a specific and sensitive detection of ADA. Additionally, anti-calf adenosine deaminase (cADA) IgY antibodies were found to be potent inhibitors of enzymatic activity of ADA.
Materials and Methods
Immunization and Antibody Isolation
Immunization of hens and isolation of IgY antibodies were performed as follows: 22-week-old White Leghorn egg-laying hens were purchased from a commercial source (Woźniak Poultry Farm, Żylice, Poland) and randomly split into two groups containing four hens each. One group received an antigen with Freund’s complete adjuvant (MP Biomedicals, Solon, OH, USA), while the control group received only an adjuvant solution. The native calf ADA (100 μg; cADA, Roche, Warsaw, Poland) was dissolved in 150 μl of 0.9% saline (Baxter, Warsaw, Poland) and emulsified with an equal amount of Freund’s adjuvant. Animals were immunized intramuscularly (Musculus pectoralis, left and right) at two different sites with 150 μl per site. The booster injections were administered after 4 and 8 weeks of primary immunization (100 μg/animal, in Freund’s incomplete adjuvant) [46, 47].
The isolation of IgY antibodies from eggs collected daily was conducted separately for each egg according to the PEG 6000 precipitation method described by Polson et al. with slight modifications [46, 53]. The purity of the obtained IgY antibodies was examined by non-reducing SDS-PAGE (4–12%, Tris-glycine) followed by Coomassie R250 staining (Calbiochem, Warsaw, Poland).
Antigen-Specific IgY Antibody Production
We used Western blot and ELISA to examine the development of hen immune response over the course of immunization as manifested by the production of specific IgYs and increased antibody avidity. For Western blot assay, calf ADA (50 ng/lane) was resolved by SDS-PAGE (4–12%, Tris-glycine) under reducing conditions and blotted (semi-dry blotting system, Cleaver Scientific, Rugby, UK) onto nitrocellulose membrane (0.45 μm, Thermo Scientific, Gdańsk, Poland). The membrane was blocked with 5% skim milk in 10 mM phosphate-buffered saline with 0.05% Tween-20, pH 7.4 (PBST; 4 °C, overnight). Next, the membrane was washed with PBST (20 min, three times) and cut into strips which were further incubated with IgY antibodies diluted 1:100 in 0.5% skim milk in PBST (1 h, 37 °C). After washing the membrane with PBST, the detection of the resulting antigen-antibody complexes was carried out with anti-IgY rabbit IgG antibodies conjugated with horseradish peroxidase (Pierce, Gdańsk, Poland) diluted 1:5000 in 0.5% skim milk in PBST. Following a 1-h incubation at 37 °C, the membrane was washed and the signal was developed with a chemiluminescent peroxidase substrate (West Pico, Pierce, Gdańsk, Poland) and the bands were visualized with the blot imaging system (Gel Logic 1500, Carestream, Rochester, NY, USA).
For an indirect ELISA, 96-well microtiter plates (MaxiSorp, Nunc, Gdańsk, Poland) were coated with calf ADA (0.5 μg/ml, 100 μl/well) in 50 mM sodium carbonate buffer, pH 9.6, followed by 3 h of incubation at 37 °C. The plates were further washed three times with PBST, and a solution of IgY antibodies isolated from egg yolks prepared in 0.5% skim milk in PBST (1:100, 100 μl/well) was added. After 1 h of incubation at 37 °C, the plates were washed with PBST as before and incubated either with 6 M urea in PBST or with PBST for 10 min at room temperature. For the detection of ADA-IgY antibody complexes, the plates were washed and rabbit anti-IgY IgG-HRP antibodies were added into each well (1:5000, prepared in 0.5% skim milk in PBST, 100 μl/well). After washing the plates, the peroxidase substrate solution (O-phenylenediamine, OPD, Pierce, Gdańsk, Poland) in 50 mM citrate buffer, pH 5.0, supplemented with 0.015% H2O2 was added (100 μl/well). The reaction was quenched by the addition of 1 M H2SO4 (50 μl/well), and absorbance at 490 nm was measured using the microplate reader (Multiskan FC, Thermo Scientific, Gdańsk, Poland). The results were expressed as the OD490 * values obtained after the subtraction of the values taken for the control antibodies. All measurements were performed in duplicate.
Titer of IgY Antibodies
The antigen-specific IgY antibody titers were determined by Western blot and ELISA analysis. For Western blot, calf ADA protein (50 ng/lane) was resolved by SDS-PAGE and blotted as described above. After blocking (4 °C, overnight), the membrane was washed in PBST and cut into strips which were incubated with the cADA-specific IgY antibody solutions prepared in 0.5% skim milk in PBST at concentrations of 50, 10, 5, 1, and 0.1 μg/ml or with control IgY antibodies (50 μg/ml) for 1 h at 37 °C. Next, the membrane strips were washed with PBST and the secondary peroxidase-conjugated antibodies were used as previously described.
For indirect ELISA assay, a microtiter plate (MaxiSorp, Nunc, Gdańsk, Poland) was coated with cADA (0.5 μg/ml, 100 μl/well) in 50 mM sodium carbonate buffer, pH 9.6 (1 h, 37 °C). The plates were washed with PBST and blocked with 5% skim milk in PBST. The wells were then washed with PBST, and the antigen-specific or control IgY antibodies at different concentrations were added (50, 10, 5, 1, 0.1 μg/ml). After 1 h of incubation (37 °C), the plate was washed and secondary antibodies were applied (anti-IgY rabbit IgG-HRP antibodies, 1:5000 in 0.5% skim milk/PBST). The plate was developed with OPD solution as described above. The results were expressed as the ELISA index (EI), where EI = ODsample/ODcontrol, with values of EI > 1.2 considered as positive .
Calf ADA Detection Limit
Different amounts ranging from 50 to 0.1 ng/lane of ADA were resolved by SDS-PAGE under reducing conditions and blotted onto a nitrocellulose membrane. After blocking (5% skim milk in PBST, 4 °C, overnight) and washing, the membrane was incubated either with IgY antibodies specific to cADA or control IgYs (10 μg/ml, 1 h, 37 °C). The ADA-IgY complexes were detected by anti-IgY rabbit IgG-HRP antibodies (1 h, 37 °C), and the bands were visualized as previously described, using chemiluminescent substrate.
In order to determine the detection limit of cADA on ELISA with anti-cADA IgY antibodies, a 96-well microtiter plate (MaxiSorp, Nunc, Gdańsk, Poland) was coated with native calf ADA at a concentration range between 1 and 0.005 μg/ml following the protocol described above. Next, the solution of anti-cADA IgYs or control IgY antibodies was added (25 μg/ml in 0.5% skim milk in PBST). After 1 h incubation at 37 °C, the plate was washed with PBST and incubated (1 h, 37 °C) with secondary antibodies conjugated to HRP. The signal development steps were as described above.
Affinity Purification of cADA-Specific IgY Antibodies
The cyanogen bromide (CNBr)-sepharose resin (Thermo Scientific, Gdańsk, Poland) was packed into the column (Micro Bio-Spin, Bio-Rad, Warsaw, Poland) and extensively washed, first with 1 mM hydrochloric acid, pH 3.0, and next with a coupling buffer (100 mM sodium hydrogen carbonate, 500 mM sodium chloride, pH 8.0) followed by the addition of cADA solution prepared in a coupling buffer (167 μg/ml, 300 μl). After a 2-h incubation at room temperature (with gentle shaking), the reaction was performed at 4 °C (overnight). Next, the resin was washed with Tris-HCl buffer (0.1 M Tris-hydrochloride, 0.5 M sodium chloride, pH 8.3), followed by incubation with Tris-HCl buffer (2 h, room temperature, gentle shaking). The resin was subsequently washed alternately with low-pH buffer (100 mM acetic acid, 100 mM sodium acetate, 500 mM sodium chloride, pH 4) and high-pH buffer (100 mM Tris-hydrochloride, 500 mM sodium chloride, pH 8.0) to elute the unbound cADA. Finally, the resin was washed with PBS and the column was stored at 4 °C until use.
In order to affinity purify anti-cADA IgY antibodies, the crude isolate (150 μl) diluted with PBS (150 μl) was applied to the prepared column containing cADA-modified sepharose and allowed to bind to the target protein (1 h, room temperature). The unbound antibodies were removed by gravity flow, and the resin was washed extensively, first with phosphate buffer supplemented with Tween-20 (10 mM PBS, 25 mM EDTA, 0.1% Tween-20), and next with PBS containing 25 mM EDTA. The anti-cADA IgY antibodies were eluted with 20 mM citrate buffer, pH 2.5. The collected fractions were immediately neutralized with Tris-base buffer (1 M, pH 8.0). After eluting the antibodies, the column was washed with PBS and stored at 4 °C for further use. The presence of IgY antibodies in collected fractions was confirmed via SDS-PAGE under non-reducing conditions, followed by silver staining .
Affinity-purified anti-cADA IgYs were further concentrated (Amicon® Ultra Centrifugal Filter; Merck, Warsaw, Poland) and dialyzed against 10 mM PBS. The total protein concentration was determined with Micro BCA assay (Pierce, Gdańsk, Poland), and the cADA-reactivity of purified antibodies was confirmed by the dot-blot analysis. For this purpose, nitrocellulose membrane was coated with cADA (0.5 μg/ml, 100 μl) and blocked with 5% skim milk in PBST (4 °C, overnight). After washing with PBST, the membrane was cut into strips which were incubated with IgY antibodies (1 μg/ml, in 0.5% skim milk in PBST): anti-cADA (crude isolate), affinity-purified anti-cADA, and control. The next steps followed the protocol described above.
Biotin-Labeled cADA-Specific IgY Antibodies
A 20-fold molar excess of freshly prepared 10 mM solution of biotin (EZ-Link™ NHS-LC-Biotin, Thermo Scientific, Gdańsk, Poland) in dimethylsulfoxide was added to the solution of anti-cADA affinity-purified IgY antibodies in PBS. The reaction was performed for 2 h at room temperature, followed by dialysis against PBS.
Double IgY Sandwich ELISA for cADA Detection
For a sensitive detection of cADA in a sandwich ELISA format, a 96-well microtiter plate (MaxiSorp, Nunc, Gdańsk, Poland) was coated with anti-cADA affinity-purified IgY or control IgY antibodies in 50 mM sodium carbonate buffer pH 9.6 (2.5 μg/ml, 100 μl/well). After incubation (4 h, 37 °C), the plate was washed with PBST and blocked with 10% skim milk in PBS (4 °C, overnight). Subsequently, the plate was washed and cADA (serial dilution ranging from 0.5 μg/ml to 50 pg/ml in PBS) was added (100 μl/well). After incubation (1 h at 37 °C), the plate was washed and biotinylated anti-cADA IgY antibodies were added (2.5 μg/ml, 0.5% skim milk in PBST). After 1 h incubation at 37 °C, the plate was washed as before and streptavidin HRP (Thermo Scientific, Gdansk, Poland) was added (1:5000 in PBST) followed by 1 h incubation at 37 °C. The plate was developed as described previously. The results were expressed as the OD490 *, where OD490 * = ODsample − ODbackground.
Detection of Human ADA Using Anti-cADA IgY Antibodies
Human recombinant ADA1 (hADA; diluted 10, 10,0 and 1000 times for silver staining and 50 times for Western blot; Sigma-Aldrich, Poznań, Poland) was resolved on SDS-PAGE, followed by either gel silver staining or electrotransfer onto the nitrocellulose membrane. For Western blot analysis, cADA was used as a positive control (1 ng/well). After blocking and washing, the membrane was incubated with anti-cADA or control IgY antibodies diluted in 0.5% skim milk in PBST (10 μg/ml, 1 h, 37 °C). Subsequently, the membrane was washed in PBST and incubated with secondary antibodies (anti-IgY rabbit IgG-HRP antibodies, 1:5000 dilution in 0.5% skim milk in PBST, 1 h, 37 °C). The signal was developed using chemiluminescent substrate, and the bands were visualized as described before.
For a specific detection of hADA on ELISA, a 96-well microtiter plate was coated with anti-cADA or control IgY antibodies in carbonate buffer pH 9.6 (2.5 μg/ml, overnight, 37 °C), followed by washing with PBST and blocking with 10% skim milk in PBST (4 °C, overnight). After washing, cADA in a dilution range from 0.5 μg/ml to 50 pg/ml and hADA in a dilution range from 100 to 10,000 were added (1 h, 37 °C). After washing with PBST, anti-cADA IgY antibodies conjugated to biotin were added (1.5 μg/ml in 0.5% skim milk in PBST, 1 h, 37 °C), followed by washing with PBST and incubation with streptavidin HRP (1:5000 in PBST, 1 h, 37 °C). The plate was developed as described previously. The results were expressed as the OD490 *, where OD490 * = ODsample − ODcontrol.
Detection of hADA in Cancer Cell Lysates
All cell lines were purchased from ATTC (Łomianki, Poland) and maintained in the Institute of Immunology and Experimental Therapy Polish Academy of Science (IIET PAS, Wroclaw, Poland). The MOLT-4 cells were cultured in RPMI + HEPES supplemented with 2 mM l-glutamine and 10% fetal bovine serum (all from Sigma-Aldrich, Steinheim, Germany). The HCV-29T and Hu1703He cells were cultured in the mixture of RPMI 1640 and Opti-MEM (1:1, v/v) medium (Gibco, Paisley, Scotland) supplemented with 2 mM l-glutamine and 5% fetal bovine serum (all from Sigma-Aldrich, Steinheim, Germany). All culture media were additionally supplemented with streptomycin (100 μg/ml; Polfa Tarchomin, Poland) and penicillin (100 U/ml; Polfa Tarchomin, Poland). Cells were cultured at 37 °C under a 5% CO2 atmosphere. Culture medium was harvested, and cell culture flasks were soaked with Trypsin-EDTA, pH 8.2 (IIET PAS, Wrocław, Poland), followed by rinsing with PBS and centrifugation (5 min, 4 °C, 300×g). Cell pellet was washed three times with PBS. Cells were lysed with RIPA buffer (Sigma-Aldrich, Steinheim, Germany) with the addition of Protease Inhibitor Cocktail (100× dilution, Sigma-Aldrich, Steinheim, Germany) for 15 min at 4 °C. Concentration of total protein in samples was determined using the Micro BCA assay (Pierce, Gdańsk, Poland). Samples were stored at − 22 °C until analysis.
The ability of anti-cADA IgY antibodies to detect ADA expressed in human cell lines was examined by Western blot. For this purpose, calf ADA (from 0.5 to 0.0625 ng/well) and cell lysates (from 40 to 2.5 μg/well of total protein) were resolved by SDS-PAGE (Tris-glycine, 4–12%) and electrotransferred onto a nitrocellulose membrane. For the detection of ADA, cADA-specific IgYs or control antibodies (1 μg/ml in 0.5% skim milk in PBST) were used following the protocol described above.
Inhibition of cADA with Specific IgY
We performed a microplate-based kinetic assay to verify whether anti-cADA IgY antibodies are able to inhibit the enzymatic activity of cADA . For this purpose, a 96-well microtiter UV-transparent plate (Thermo Scientific, Gdańsk, Poland) was blocked with 2% bovine serum albumin (VWR International, Gdańsk, Poland) in PBS (150 μl/well, 1 h, 37 °C). Next, the plate was washed with PBS (three times, manually, 300 μl/well) and IgY antibodies (specific or control; concentration range from 111.11 to 9.54 nM in PBS buffer, pH 7.2) and cADA (0.04 U/ml) were added to the wells. After 30 min of incubation at 37 °C, adenosine (1.25 mM, PBS buffer, pH 7.2; Carl Roth GmbH, Karlsruhe, Germany) was added. The change of absorbance at 260 nm was monitored on a SpectraMax Plus 384 microplate reader (Molecular Devices, Sunnyvale, CA, USA) for 3 h at room temperature.
All data were analyzed using GraphPad Prism version 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). The results are presented as the mean ± SEM of experiments performed in duplicate or as the mean ± SD of two independent experiments performed in duplicate.
Results and Discussion
Immunization and Isolation of IgY Antibodies
Hens immunized with cADA emulsified with Freund’s complete (for primary immunization) and incomplete (for booster injections) adjuvant showed no signs of pain or stress over the course of 22 weeks. Antibodies isolated from egg yolks using the PEG 6000 precipitation method showed a purity of 85–90% (as examined by SDS-PAGE followed by a silver staining method) with an average isolation yield of approximately 90 mg per single egg yolk .
Specific IgY Antibody Production
Reactivity of cADA-Specific Antibodies
Electrophoretic analysis of ADA purified from calf intestine revealed the presence of two bands (40.3 kDa, 33.3 kDa; Fig. 3a) which is in agreement with previous findings by Cory et al. . Similarly to the result obtained after Western blot analysis, the cADA detection limit on ELISA was equal to 0.1 μg/ml with an EI > 1.2 (Fig. 3b).
Affinity Purification of Anti-cADA IgY Antibodies
Development of a Sandwich ELISA for a Specific Detection of cADA
Detection of Human ADA
Detection of hADA in Lysate of Different Human Cancer Cell Lines
The species cross-reactivity of anti-cADA IgY antibodies allows for future development of sensitive assays aimed at detecting hADA.
Inhibition of Calf ADA Activity by Specific IgY Antibodies
The potential application of ADA as a diagnostic marker of various types of cancer including breast, bladder, ovary, tongue, and intestine highlights the usefulness of the method presented here [22, 23, 24, 28, 29]. The developed IgY-based sensitive ADA detection assay applies polyclonal hen egg-yolk antibodies for capture and detection of the target antigen in a sandwich ELISA format. The anti-cADA IgY antibodies were able to specifically recognize ADA in human cancer cell lysates. Such cross-reactivity of IgY antibodies obtained through immunization of hens with calf ADA is only possible due to a high homology between both proteins. Considering the fact that current ADA diagnostic testing relies mainly on the measurement of its enzymatic activity, based on the Giusti and Galanti method, our proposed assay could provide an alternative diagnostic option . The studies regarding this are ongoing in our laboratory.
This work was supported by the National Center for Research and Development (grant number LIDER/08/90/l-1/09/NCBiR/2010). M. Sieńczyk, R. Grzywa, and J. Oleksyszyn are thankful to Wrocław University of Science and Technology for support (Statute Funds 0401/0250/16 into S50129/Z0313). The authors would like to thank Prof. Rafał Latajka for sharing some equipment used for enzyme kinetic studies. The authors would like to thank Dr. Keri Csencsits-Smith (University of Texas at Houston) for critical reading of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.
Animal experimentation was approved by the Ethics Committee for Animal Experiments of the Wroclaw University of Environmental and Life Sciences in Wroclaw, Poland (Permit Number: 52/2010), and conducted in compliance with local and national guidelines. Animals were housed under conventional conditions and continuously monitored for any signs of distress and pain in the Vivarium of the Wroclaw University of Environmental Science, Faculty of Veterinary Medicine (Wroclaw, Poland).
- 9.Ungerer, J. P., Oosthuizen, H. M., Bissbort, S. H., & Vermaak, W. J. (1992). Serum adenosine deaminase: isoenzymes and diagnostic application. Clinical Chemistry, 38(7), 1322–1326.Google Scholar
- 19.Eriksson, S., Graslund, A., Skog, S., Thelander, L., & Tribukait, B. (1984). Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis. The Journal of Biological Chemistry, 259(19), 11695–11700.Google Scholar
- 26.Mishra, R., Agarwal, M. K., & Chansuria, J. P. (2000). Serum adenosine deaminase levels as an index of tumor growth in head and neck malignancy. Indian Journal of Otolaryngology and Head & Neck Surgery, 52(4), 360–363.Google Scholar
- 27.Sharma, S. D. P. B., & Metgudmath, R. B. (2013). Evaluation of serum adenosine deaminase and retinol in patients with laryngeal cancer. Indian Journal of Pharmaceutical and Biological Research, 1(4), 30–34.Google Scholar
- 30.Blake, J., & Berman, P. (1982). The use of adenosine deaminase assays in the diagnosis of tuberculosis. South African Medical Journal, 62(1), 19–21.Google Scholar
- 35.Hodek, P., & Stibrova, M. (2003). Chicken antibodies—superior alternative for conventional immunoglobulins. Proceedings of the Indian National Science Academy, 4, 461–468.Google Scholar
- 36.Michael, A., Meenatchisundaram, S., Parameswari, G., Subbraj, T., Selvakumaran, R., & Ramalingam, S. (2010). Chicken egg yolk antibodies (IgY) as an alternative to mammalian antibodies. Indian Journal of Science and Technology, 3(4), 468–474.Google Scholar
- 37.Schade, R., Calzado, E. G., Sarmiento, R., Chacana, P. A., Porankiewicz-Asplund, J., & Terzolo, H. R. (2005). Chicken egg yolk antibodies (IgY-technology): a review of progress in production and use in research and human and veterinary medicine. Alternatives to Laboratory Animals, 33(2), 129–154.Google Scholar
- 39.Pauly, D., Chacana, P. A., Calzado, E. G., Brembs, B., & Schade, R. (2011). IgY technology: extraction of chicken antibodies from egg yolk by polyethylene glycol (PEG) precipitation. Journal of Visualized Experiments. https://doi.org/10.3791/3084(51.
- 40.Kim, S. H., Park, M. K., Kim, J. Y., et al. (2005). Development of a sandwich ELISA for the detection of Listeria spp. using specific flagella antibodies. Journal of Veterinary Science, 6(1), 41–46.Google Scholar
- 42.Brujeni, G. N., & Gharibi, D. (2012). Development of DNA-designed avian IgY antibodies for detection of Mycobacterium avium subsp. paratuberculosis heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serum of normal cattle. Applied Biochemistry and Biotechnology, 167(1), 14–23.CrossRefGoogle Scholar
- 49.Liu, S., Dong, W., & Kong, T. (2010). Preparation and characterization of immunoglobulin yolk against the venom of Naja naja atra. Indian Journal of Experimental Biology, 48(8), 778–785.Google Scholar
- 54.Silva, D. A., Silva, N. M., Mineo, T. W., Pajuaba Neto, A. A., Ferro, E. A., & Mineo, J. R. (2002). Heterologous antibodies to evaluate the kinetics of the humoral immune response in dogs experimentally infected with Toxoplasma gondii RH strain. Veterinary Parasitology, 107(3), 181–195.CrossRefGoogle Scholar
- 55.Celis J.E., & Gromova, I. (2006). in Cell biology: A Laboratory Handbook, 3rd Edition, vol. 4: Protein detection in gels by silver staining: a procedure comparable with mass-spectrometry. (Celis, J.E., ed.) Academic Press, pp. 219-223.Google Scholar
- 60.Shin, J. H., Yang, M., Nam, S. W., et al. (2002). Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clinical and Diagnostic Laboratory Immunology, 9(5), 1061–1066.Google Scholar
- 63.Giusti, G., & Galanti, B. (1984). Methods of enzymatic analysis (3rd ed.pp. 315–323). Weinheim: Verlag Chemie.Google Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.